These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19713713)

  • 21. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
    Pritchard KI
    Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
    [No Abstract]   [Full Text] [Related]  

  • 22. Progression-free survival in neuroendocrine tumors: preferred end point, but how should it be defined?
    Riechelmann RP; Rego J
    J Clin Oncol; 2011 Jul; 29(20):2835-6. PubMed ID: 21632510
    [No Abstract]   [Full Text] [Related]  

  • 23. Neuroendocrine tumours of the pancreas.
    Eriksson B; Oberg K
    Br J Surg; 2000 Feb; 87(2):129-31. PubMed ID: 10671915
    [No Abstract]   [Full Text] [Related]  

  • 24. The medical management of malignant disease.
    Smith I
    Trans Med Soc Lond; 1986-1987; 103():18-20. PubMed ID: 2472030
    [No Abstract]   [Full Text] [Related]  

  • 25. [Management of metastatic neuroendocrine tumors].
    Baudin E; Guigay J; Ducreux M; Duvillard P
    Ann Pathol; 2011 Nov; 31(5 Suppl):S85-6. PubMed ID: 22054472
    [No Abstract]   [Full Text] [Related]  

  • 26. [Mono-polychemotherapeutic treatment? The opportunities and limits].
    Carreca I; Dispenza J; Agueli R; Cucciarrè S
    Minerva Med; 1999; 90(7-8):203-4. PubMed ID: 10719418
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
    Larsson DE; Hassan S; Larsson R; Oberg K; Granberg D
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):5-12. PubMed ID: 19381631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
    Ewer MS; Lippman SM
    J Clin Oncol; 2005 May; 23(13):2900-2. PubMed ID: 15860848
    [No Abstract]   [Full Text] [Related]  

  • 29. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors.
    Kianmanesh R; Ruszniewski P; Rindi G; Kwekkeboom D; Pape UF; Kulke M; Sevilla Garcia I; Scoazec JY; Nilsson O; Fazio N; Lesurtel M; Chen YJ; Eriksson B; Cioppi F; O'Toole D;
    Neuroendocrinology; 2010; 91(4):333-40. PubMed ID: 20424420
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of neuroendocrine tumors: a meeting of experts from Latin America.
    Costa F; Domenichini E; Garavito G; Medrano R; Mendez G; O'Connor J; Rojas W; Torres S; Younes RN; Delle Fave G; Oberg K
    Neuroendocrinology; 2008; 88(3):235-42. PubMed ID: 18663282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors.
    Kos-Kudła B; O'Toole D; Falconi M; Gross D; Klöppel G; Sundin A; Ramage J; Oberg K; Wiedenmann B; Komminoth P; Van Custem E; Mallath M; Papotti M; Caplin M;
    Neuroendocrinology; 2010; 91(4):341-50. PubMed ID: 20484875
    [No Abstract]   [Full Text] [Related]  

  • 32. Neuroendocrine tumors a rare finding: part I.
    Jacobs C
    Clin J Oncol Nurs; 2009 Feb; 13(1):21-3. PubMed ID: 19193545
    [No Abstract]   [Full Text] [Related]  

  • 33. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update.
    Salazar R; Wiedenmann B; Rindi G; Ruszniewski P
    Neuroendocrinology; 2012; 95(2):71-3. PubMed ID: 22262042
    [No Abstract]   [Full Text] [Related]  

  • 34. Bevacizumab and subtype-adapted chemotherapy backbone in neuroendocrine tumors.
    Hadoux J; Ducreux M
    J Clin Oncol; 2013 Mar; 31(7):976-7. PubMed ID: 23358990
    [No Abstract]   [Full Text] [Related]  

  • 35. Initial treatment of well-differentiated neuroendocrine tumors.
    Dasari A; Yao J
    Oncology (Williston Park); 2014 Nov; 28(11):945-7. PubMed ID: 25741544
    [No Abstract]   [Full Text] [Related]  

  • 36. ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors.
    Pavel M; Grossman A; Arnold R; Perren A; Kaltsas G; Steinmüller T; de Herder W; Nikou G; Plöckinger U; Lopes JM; Sasano H; Buscombe J; Lind P; O'Toole D; Oberg K;
    Neuroendocrinology; 2010; 91(4):326-32. PubMed ID: 20453466
    [No Abstract]   [Full Text] [Related]  

  • 37. [Current aspects and medication therapy strategies for out-patient uro-oncological therapy].
    Rinnab L; Küfer R
    Urologe A; 2009 Nov; 48(11):1261-2. PubMed ID: 19844671
    [No Abstract]   [Full Text] [Related]  

  • 38. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms.
    Caplin M; Sundin A; Nillson O; Baum RP; Klose KJ; Kelestimur F; Plöckinger U; Papotti M; Salazar R; Pascher A;
    Neuroendocrinology; 2012; 95(2):88-97. PubMed ID: 22261972
    [No Abstract]   [Full Text] [Related]  

  • 39. Bevacizumab plus temozolomide: a novel treatment option for advanced neuroendocrine tumors?
    Koumarianou A; Kaltsas G
    J Clin Oncol; 2013 Mar; 31(7):975-6. PubMed ID: 23358970
    [No Abstract]   [Full Text] [Related]  

  • 40. Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts?
    Bergsland EK
    J Clin Oncol; 2015 May; 33(14):1523-6. PubMed ID: 25646187
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.